Improving the evidence base of Markov models used to estimate the costs of scaling up antiretroviral programmes in resource-limited settings

摘要

BackgroundDespite concerns about affordability and sustainability, many models of the lifetime costs of antiretroviral therapy (ART) used in resource limited settings are based on data from small research cohorts, together with pragmatic assumptions about life-expectancy. This paper revisits these modelling assumptions in order to provide input to future attempts to model the lifetime costs and the costs of scaling up ART.